tbuckley/cabot-search huggingface dataset:
PET-FDG as a predictor of efficacy of Sunitinib in patients with metastatic GIST, progressing after treatment of Imatinib 400 mg/day
Authors: G. Badalamenti, F. Fulfaro, C. Ancona, B. Vincenzi, G. Grignani, S. Bartolotta, L. Incorvaia, D. Piazza, A. Russo
Journal: Annals of Oncology (2015)
Allogeneic HY antibodies detected 3 months after female-to-male HCT predict chronic GVHD and nonrelapse mortality in humans
Authors: Hideki Nakasone, Lu Tian, Bita Sahaf, Takakazu Kawase, Kelsi Schoenrock, Spenser Perloff, Christine E. Ryan, Jed Paul, Rakesh Popli, Fang Wu, Joanne M. Otani, John Coller, Edus H. Warren, David B. Miklos
Journal: Blood (2015)
Outcomes for patients treated with or without bevacizumab on SWOG S0819: A randomized, phase III study comparing carboplatin/Paclitaxel or carboplatin/Paclitaxel/bevacizumab with or without concurrent cetuximab in patients with advanced non-small cell lung cancer (NSCLC).
Authors: Thomas John Semrad, Mary Weber Redman, Roy S. Herbst, Edward S. Kim, Lyudmila Bazhenova, Gregory A. Masters, Kurt R. Oettel, Perry Guaglianone, Christopher M. Reynolds, Anand B. Karnad, Susanne M. Arnold, Marileila Varella-Garcia, James Moon, Philip C. Mack, Charles David Blanke, Fred R. Hirsch, Karen Kelly, David R. Gandara
Journal: Journal of Clinical Oncology (2016)

9082 Background: Bevacizumab (Bev) combined with chemotherapy improves survival in selected patients (pts) with advanced, nonsquamous NSCLC. However, the benefit of Bev has been questioned in certain populations and optimal selection criteria are debated. Methods: SWOG S0819 randomly assigned 1,313 eligible pts with advanced NSCLC to chemotherapy (+/- Bev) with or without cetuximab. Protocol defined criteria for Bev Exclusion (BE) were > 50% squamous cell (SCCA), cavitary lung lesion, hemoptysis ( > 1/2 tsp), coagulopathy, CNS metastasis (until 6/2013), non-healing wound or fistula, anticoagulation, platelet inhibitor, or INR > 1.5. Investigators or pts could also choose BE assignment. We conducted subset analyses to compare the baseline characteristics and treatment outcomes for Bev-included (BI) versus BE pts, as well as BE subsets defined by the protocol (BE-Inappropriate) or patient/investigator choice (BE-Choice). Results: BI pts (42.2%) had superior outcomes to BE pts (Table). The reason for BE was ascertained in 94.2%; most commonly SCCA (44.4%), choice (20%), and anticoagulant or platelet inhibitor (19.1%). Multiple reasons were present in 25.6%. There were no significant differences in age, gender, race/ethnicity, PS, or weight loss between BI and BE pts and no differences between BE-Choice and BE-Inappropriate pts. BE-Choice pts had improved PFS but not OS compared to BE-Inappropriate pts. Conclusions: BI pts with advanced NSCLC on S0819 had better survival than BE pts, approximating those of ECOG 4599. The demographics of BI, BE-Choice, and BE-Inappropriate pts were similar; however, BE-Choice pts had survival outcomes more similar to BE-Inappropriate pts than to those treated with Bev. Support: NIH/NCI/NCTN grants SWOG: CA180888, CA180819; ECOG/ACRIN: CA180820; Alliance: CA180821; and in part by Eli Lilly and Company Clinical trial information: NCT00946712. N PFS (mo) HR OS (mo) HR BI 554 5.7 0.61 (0.54-0.68) 12.1 0.72 (0.64-0.81) BE 759 4.0 P < 0.001 8.5 P < 0.001 BE-Choice 143 4.3 0.78 (0.64-0.94) 8.6 0.84 (0.69-1.04) BE-Inappropriate 572 3.9 P < 0.01 8.5 P = 0.11
Partial Isolation and Characterization off Antigen(s) Associated With Murine Melanoma 2
Authors: Jean-Claude Bystryn, Isaac Schenkein, Sonia Baur, Jonathan W. Uhr
Journal: JNCI Journal of the National Cancer Institute (1974)

Antigen(s) associated with murine B16 melanoma (MAA) were radiolabeled by the incubation of tumor cells with 3H-leucine and identified by an antigen-binding radioimmunoassay. The MAA had a molecular weight of 150,000–200,000 daltons, were precipitable by 52% ammonium sulfate, and were inactivated by treatment with heat, acid, base, trypsin, or papain. Treatment with neuraminidase greatly increased MAA antigenicity. These results suggest that MAA are glycoproteins. Some MAA were present to a lesser and variable extent in normal syngeneic murine fibroblasts. MAA were released into culture medium by tumor cells and to a lesser extent by normal cells.
Preliminary data from a multi-arm expansion study of MEDI4736, an anti-PD-L1 antibody.
Authors: Neil Howard Segal, Scott Joseph Antonia, Julie R. Brahmer, Michele Maio, Andy Blake-Haskins, Xia Li, Jim Vasselli, Ramy A. Ibrahim, Jose Lutzky, Samir Khleif
Journal: Journal of Clinical Oncology (2014)

3002^ Background: Checkpoint blockade of the PD-1/PD-L1 and CTLA-4 pathways has shown to be active in multiple tumor types. MEDI4736 is a human IgG1 monoclonal antibody which binds specifically to PD-L1, preventing binding to PD-1 and CD80. In phase I, MEDI4736 showed acceptable safety (no maximal tolerated dose identified). With evidence of clinical activity in phase I, an expansion study was initiated in multiple cancer types including NSCLC, melanoma (cutaneous and ocular), gastroesophageal, hepatocellular carcinoma, pancreatic, SCCHN and triple negative breast cancer. Methods: 10 - 20 pts were initially enrolled per tumor type, with expansion allowed upon observation of clinical activity. MEDI4736 was administered as 10 mg/kg IV every 2 weeks for 12 months. Retreatment was permitted for progression after 12 months of therapy. Response was assessed by RECIST v1.1. Results: The expansion cohorts were initiated in Sep 2013. As of Jan 17, 2014, 151 pts had received ≥1 dose of MEDI4736. Safety data are available for 105 pts (median age 60y; 36-84), 59% male, ECOG 0/1 (27%/71%), with a median of 3 (1-8) prior treatments, who received a median of 3 (1-8) doses. The safety profile was consistent with previous reports. Treatment-related AEs occurred in 33% of pts, with related ≥ Grade 3 AEs in 7%; none led to discontinuation of study drug. The most frequently observed treatment-related AEs were fatigue (13%), nausea (8%), rash (6%), vomiting (5%), and pyrexia (5%). One pt developed Grade 2 pneumonitis which resolved with drug interruption and steroids. There were no reports of colitis or hyperglycemia of any grade. With a median follow-up of 6 weeks, tumor shrinkage is already detectable in multiple tumor types including pts with melanoma, pancreatic, head and neck, and gastroesophageal cancer. The study continues to enroll pts and generate more mature follow-up data. Conclusions: Preliminary data in expansion suggest the safety of MEDI4736 is acceptable, even in heavily pre-treated pts. Early evidence of clinical activity was reported in multiple tumor types. Further evaluation of MEDI4736 as monotherapy and in combination with a variety of immunomodulators and targeted agents is ongoing. Clinical trial information: NCT01693562.
The lowest common denominator between species for teaching behaviors
Authors: Arnaud Badets, François Osiurak
Journal: Behavioral and Brain Sciences (2015)

We propose that an underestimated albeit fundamental mechanism in teaching behavior is perceptual resonance. With this mechanism, many animals, including humans, are able to learn from each other by sharing and processing relevant events in the environment. For teaching, we suggest a triadic principle involving the teacher, the learner, and the events to be learned from the world.
ACTH and Cortisone in the Treatment of Ocular Disease
Authors: Richmond W. Smith, Ellis H. Steffensen
Journal: New England Journal of Medicine (1951)

Clinical Aspects of Parenteral Administration of ACTH and CortisoneAs one might expect, the type of ocular lesion has not determined which of the two hormonal agents should be employed. Olson and others,13 in summarizing their experiences with ACTH and cortisone, obtained generally identical results with both drugs in a series of 51 cases. These investigators reported similar findings at the Second Clinical ACTH conference,10 at which 97 cases were added to the original series. In some cases, there may be physical findings that justify the selective use of one of the hormones. Thus, in patients with such clinical states . . .
The 30 Million–Word Gap
Authors: Jenny S. Radesky, Judith Carta, Megan Bair-Merritt
Journal: JAMA Pediatrics (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal
Failure to detect a huge Meckel's diverticulum with abundant ectopic gastric mucosa on gastric mucosal scintigraphy with Tc-99m pertechnetate.
Authors: MISAKO ARIGA, KAZUYOSHI SUGA, NAOFUMI MATSUNAGA, KAZUHIKO SASAI, KENSAKU SHIMIZU, YUKO ISHIKAWA, AKIRA TANGOKU, RYUICHI ETO
Journal: Clinical Nuclear Medicine (2001)

ARIGA, MISAKO M.D.; SUGA, KAZUYOSHI M.D.; MATSUNAGA, NAOFUMI M.D.; SASAI, KAZUHIKO M.D.; SHIMIZU, KENSAKU M.D.; ISHIKAWA, YUKO M.D.; TANGOKU, AKIRA M.D.; ETO, RYUICHI M.D. Author Information
Abstract 4754: Development of fluorescent probes for detection of DNA base excision repair in human cancer cells
Authors: Allison G. Condie, Yan Yan, Stanton L. Gerson, Yanming Wang
Journal: Cancer Research (2015)

Abstract Many cancer chemotherapeutics target DNA, which makes them vulnerable to repair by innate mechanisms the cell has evolved to ward off endogenous and exogenous DNA damage. In the course of chemotherapy, these repair pathways lead to drug resistance and reduced efficacy of cancer treatment. To address these issues, our goal was to develop imaging agents to visualize and quantify DNA repair in cancer. Thus, we have developed small molecule, fluorescent probes that bind to the abasic (or AP for apurinic/apyrimidinic) site in DNA, a key intermediate in the base excision repair (BER) pathway. Taking advantage of the biochemistry of BER, we have developed an assay based on a fluorescently tagged DNA oligomer to evaluate the ability of these probes to bind to AP sites and stall further repair. This assay relies on blocking the DNA single strand breaking activity of the enzyme, AP endonuclease (APE), when its natural substrate, the AP site, is obstructed by probe binding. Using this assay, we have screened our novel probes for their AP site binding potential. Our cyanine-(Cy7) based probe outperformed other, commercially available AP site binding probes including methoxyamine (MX) and aldehyde reactive probe (ARP). In addition, we have developed a method for analyzing a genomic DNA sample that demonstrates the potential to evaluate physiologically relevant quantities of AP sites. 5-Fluoro-2′-deoxyuridine (FUDR) is indicated for treatment of many types of cancer; however, uracil DNA glycosylase (UDG) can repair the lesions in DNA introduced by FUDR. Therefore, we prepared a UDG knockdown of the DLD1 colon cancer cell line and treated both wild type and knockdown cells with FUDR for 24, 48, and 72 h. Following extraction of the DNA and in vitro treatment with purified UDG, we observed a nearly 9-fold increase in fluorescence in treated versus untreated cells. This confirmed that our probe could report of AP site quantity in cancer cells in vitro. Our cyanine-based probes have several benefits over existing probes including red and NIR fluorescence for application in animal imaging. Our studies indicate that these probes bind to AP sites more efficiently than existing probes. Further, these fluorescent AP site-binding agents could have application in drug development and discovery or be used in assays to monitor patient response to therapy. Citation Format: Allison G. Condie, Yan Yan, Stanton L. Gerson, Yanming Wang. Development of fluorescent probes for detection of DNA base excision repair in human cancer cells. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 4754. doi:10.1158/1538-7445.AM2015-4754
Condomless Sex With Virologically Suppressed HIV-Infected Individuals
Authors: Eric S. Daar, Katya Corado
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Waking up in the zone with Sleep Cycle
Authors: Michele Lastella, Gregory Daniel Roach, Charli Sargent
Journal: British Journal of Sports Medicine (2016)

Sleep Cycle alarm clock.

Health and fitness.

iOS 8.0 or later/Andriod 4.0 or later.

Free for iPhone; Android $A1.49.

Sleep is an essential component for athletes due to its physiological and psychological restorative effects.1 Sleep is categorised into two main phases, non-rapid eye movement (NREM) sleep which consists of progressively deeper sleep stages 1, 2 and 3 and REM sleep.2 While REM is associated with learning and memory processes, slow-wave sleep (SWS; NREM 3), the deepest sleep stage is where growth hormones are secreted stimulating protein synthesis necessary for muscle repair and growth.3 Despite conflicting research; when sleep is interrupted during the wrong sleep stage (ie, SWS and REM) it may result in lower levels …
A Complex Molecular Network Controls Palmitoylation-Dependant CD95 Sensitivity Of CLL Cells
Authors: Valeska Berg, Nachiket Vartak, Rainer Claus, Julia Claasen, Marion Rusch, Christian P. Pallasch, Herbert Waldmann, Christopher Plass, Philippe Bastiaens, Michael Hallek, Christian Hedberg, Clemens Wendtner, Lukas P. Frenzel
Journal: Blood (2013)
HHS Awards Funds for Health Center Renovation and Expansion
Authors: Julie A. Jacob
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Strict Treatment Regimen and Febrile Neutropenia Guidelines Allow Favorable Outcomes for Pediatric ALL in Southern India
Authors: Neeraj Sidharthan, Rema Ganapathy, P Gangadharan, Sumi Soman, Keechilet Pavithran, Raghuveer Prabhu, Haripriya V Raju, Ayswarya Rajan, Pavankumar Boyella, Rajeswari Arun, Scott C. Howard, Asha Pillai
Journal: Blood (2015)
Granulocyte-Macrophage Colony-Stimulating Factor–Activated Signaling Pathways in Human Neutrophils. I. Tyrosine Phosphorylation-Dependent Stimulation of Phosphatidylinositol 3-Kinase and Inhibition by Phorbol Esters
Authors: Amin Al-Shami, Sylvain G. Bourgoin, Paul H. Naccache
Journal: Blood (1997)
Urinary MHPG and clinical response to amitriptyline in depressed patients
Authors: D G Spiker, D Edwards, I Hanin, J F Neil, D J Kupfer
Journal: American Journal of Psychiatry (1980)

The authors treated 18 rigorously diagnosed depressed patients with amitriptyline after baseline urine samples were collected for the measurement of 3-methoxy-4-hydroxphenylglycol (MHPG). Neither age nor severity of depression before treatment correlated with MHPG excretion. There was also no significant correlation between baseline MHPG excretion and clinical response at the end of at least 25 days' treatment with amitriptyline. The authors discuss the relevance of amitriptyline and nortriptyline plasma levels to MHPG and the noradrenergic/serotonergic theories of depression.
Clinical Impact of Additional Cytogenetic Aberrations and Complex Karyotype In Pediatric 11q23/MLL-Rearranged AML: Results from an International Retrospective Study
Authors: Eva A Coenen, Susana C. Raimondi, Jochen Harbott, Zimmermann Martin, Brian V Balgobind, Todd A. Alonzo, Anne Auvrignon, Berna Beverloo, Myron Chang, Ursula Creutzig, Michael Dworzak, Erik Forestier, Brenda Gibson, Henrik Hasle, Christine J Harrison, Nyla A. Heerema, Gertjan J. Kaspers, Anna Leszl, Nathalia Litvinko, Luca lo Nigro, Akira Morimoto, Christine Perot, Dirk Reinhardt, Jeffrey Rubnitz, Franklin O. Smith, Jan Stary, Irina Stasevich, Sabine Strehl, Takashi Taga, Daisuke Tomizawa, David Webb, Zuzana Zemanova, Rob Pieters, C. Michel Zwaan, Marry van den Heuvel-Eibrink
Journal: Blood (2010)
Abstract 5615: Dual Role of the Small G Protein Rac-1 in the Regulation of Hypoxia-Induced STAT3 Activation in Endothelial Cells
Authors: Mohamed Labazi, Folami Lamoke, Dennis M Marcus, Ruth B Caldwell, Manuela Bartoli
Journal: Circulation (2009)

The Signal Transducer and Activator of Transcription 3 (STAT3) is a critical regulator of Vascular Endothelial Growth factor (VEGF) expression and activity in cardiac muscle and vascular endothelial cells. We have previously shown that hypoxia-induced activation of STAT3 is a redox-dependent event and can be blocked by inhibitors of NAD(P)H oxidase activity. Here we investigated the specific role of the small G protein Rac-1 in the regulation of hypoxia-induced STAT3 activation in endothelial cells. Human umbilical vein endothelial cells (HUVEC) and human coronary endothelial cells in culture were subjected to 2% oxygen levels for different times (10min, 30min). Rac-1 inhibition was achieved by transfection of ECs with specific siRNA or by treatments of the cells with 75 μ M of the Rac-1 inhibitor NSC23766 (EMD Biosciences). Chromatin immunoprecipitation (ChIP) was conducted to assess STAT3 transcriptional activity. STAT3 phosphorylation and protein-protein association was measured by Western blotting and immunoprecipitation analysis (respectively). We found that inhibition of Rac-1 activity by siRNA or by treatment with NSC23766 blocks STAT3 binding to VEGF promoter in hypoxic conditions compared to treatment of the cells with scramble siRNA or vehicle only. This effect correlated with blockade of hypoxia-induced STAT3 tyrosine phosphorylation at tyrosine 705 and at serine 727. In addition, hypoxia-stimulated Rac-1 binding to STAT3 at 30 minutes and inhibition of Rac-1 activity stimulated STAT3 binding to Protein Inhibitor of STAT3 (PIAS3) responsible for its sumoylation/inactivation. Taken together our results suggest that Rac-1 activity is associated with hypoxia-stimulated STAT3 activation and STAT3-dependent VEGF by regulating its phosphorylation/activation as well its sumoylation via blockade of STAT3 binding to PIAS3. These data disclose a previously uncovered activity of Rac-1 in the regulation of STAT3 inactivation by sumoylation.
More doctors are engaged in commissioning under CCGs
Authors: Gareth Iacobucci
Journal: BMJ (2016)

Clinical commissioning groups (CCGs) have secured better clinical engagement than previous forms of commissioning in England but need greater support from politicians to make “tough prioritisation decisions,” a new report has found.

The study by the healthcare think tanks the King’s Fund and the Nuffield Trust looked at how six CCGs had developed GP led commissioning since 2013 and surveyed GP leaders and members in these groups over four years.1

Some 70% of the CCG members polled said they felt at least “somewhat” engaged with the work of their local group between 2013 and 2016. This compared favourably with the results of similar surveys conducted in …
Can You Restore My “Own” Body? A Phenomenological Analysis of Relational Autonomy
Authors: Jenny Slatman, Kristin Zeiler, Ignaas Devisch
Journal: The American Journal of Bioethics (2016)

When retrospectively analyzing their reasoning in relation to a case of a patient who wanted and eventually had his implantable cardioverter defibrillator (ICD) removed, Pullman and Hodgkinson (201...
Cervical cerclage for prevention of preterm delivery in women with short cervix. Authors' reply
Authors: Bissallah Ekele, Lydia Airede, R. Simcox, P. R. Bennett, A. H. Shennan, Meekai To, Zarko Alfirevic, Paula Williamson, Kypros Nicolaides
Journal: The Lancet (2004)
Prognostic Determinants of Coronary Atherosclerosis in Stable Ischemic Heart Disease
Authors: Amir Ahmadi, Gregg W. Stone, Jonathon Leipsic, Leslee J. Shaw, Todd C. Villines, Morton J. Kern, Harvey Hecht, David Erlinge, Ori Ben-Yehuda, Akiko Maehara, Eloisa Arbustini, Patrick Serruys, Hector M. Garcia-Garcia, Jagat Narula
Journal: Circulation Research (2016)

Risk stratification in patients with stable ischemic heart disease is essential to guide treatment decisions. In this regard, whether coronary anatomy, physiology, or plaque morphology is the best determinant of prognosis (and driver an effective therapeutic risk reduction) remains one of the greatest ongoing debates in cardiology. In the present report, we review the evidence for each of these characteristics and explore potential algorithms that may enable a practical diagnostic and therapeutic strategy for the management of patients with stable ischemic heart disease.